Dieter Falkenburg
Directeur Général chez Novoplant GmbH
Profil
Dieter Falkenburg has been Chief Executive Officer of Novoplant GmbH since May 2004.
He joined ASTA Medica in 1990 as Manager of International Business Development.
He was appointed as Vice President of Business Development for MPB Cologne and Executive Vice President of Business Development for Direvo AG in 1999.
Dr. Falkenburg received a PhD from Ruprecht Karls University, Heidelberg.
Postes actifs de Dieter Falkenburg
Sociétés | Poste | Début |
---|---|---|
Novoplant GmbH
Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Directeur Général | - |
Anciens postes connus de Dieter Falkenburg
Sociétés | Poste | Fin |
---|---|---|
ASTA Medica Oncology | Corporate Officer/Principal | - |
Formation de Dieter Falkenburg
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Novoplant GmbH
Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Process Industries |
ASTA Medica Oncology |